9 Meters Biopharma Inc. (NMTRQ)
| Market Cap | 1.45K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -46.28M |
| Shares Out | 13.59M |
| EPS (ttm) | -3.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,251 |
| Open | n/a |
| Previous Close | 0.0001 |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | 1.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About NMTRQ
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to preven... [Read more]
Financial Performance
Financial StatementsNews
Drug developer 9 Meters Biopharma files for bankruptcy protection
Drug developer 9 Meters Biopharma and its units have filed for Chapter 11 bankruptcy protection, it said in a regulatory filing on Tuesday, sending its shares tumbling 66% in premarket trading.
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today an...
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today pr...
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today a...
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
RALEIGH, NC / ACCESSWIRE / March 28, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today ...
9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
RALEIGH, NC / ACCESSWIRE / March 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announ...
9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
RALEIGH, NC / ACCESSWIRE / March 14, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announ...
9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
RALEIGH, NC / ACCESSWIRE / March 7, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today a...
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
RALEIGH, NC / ACCESSWIRE / January 31, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, toda...
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome
Study design incorporates two primary endpoints to evaluate the efficacy of vurolenatide in short bowel syndrome with or without parenteral support dependence Study design allows for the assessment of...
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy
Collaboration focuses on the relationship between intestinal microbiome composition and systemic responses to cancer treatments and builds upon additional positive preclinical data with investigationa...
9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific Meeting
Preclinical data investigated the use of glucose-dependent insulinotropic polypeptide (GIP) monoclonal antibodies (mAbs) to prevent and treat obesity in animal models Poster granted Outstanding Resear...
9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
RALEIGH, NC / ACCESSWIRE / October 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, anno...
9 Meters Biopharma Announces 1-for-20 Reverse Stock Split
RALEIGH, NC / ACCESSWIRE / October 17, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, anno...
9 Meters Biopharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference
RALEIGH, NC / ACCESSWIRE / September 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, ann...
9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress
RALEIGH, NC / ACCESSWIRE / September 1, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, tod...
9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma Conference
RALEIGH, NC / ACCESSWIRE / August 31, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, annou...
9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
Positive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announced Vurolenatide End-of-Phase 2 meeting with FDA on track for 3Q Cash balance as of June 30, 2022 ...
9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announce...
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel Syndrome RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical...
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
Phase 2 VIBRANT study identifies a dose and dosing interval with >25% improvement in the primary endpoint of 24-hour mean total stool output reduction over 6 weeks Vurolenatide was generally well tole...
Why Are 9 Meters Biopharma Shares Plunging Today?
9 Meters Biopharma Inc (NASDAQ: NMTR) completed a pre-specified interim analysis for the Phase 3 study of larazotide for patients with celiac disease who continue to experience gastrointestinal sympto...
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
Additional analyses to determine if a subgroup of patients and/or symptoms may have been responsive to treatment Company remains on track to deliver vurolenatide Phase 2 short bowel syndrome results b...
9 Meters Biopharma to Participate in the 2022 BIO International Convention
RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announc...
9 Meters Biopharma to Exhibit at Digestive Disease Week 2022
RALEIGH, NC / ACCESSWIRE / May 19, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announce...